Search Results
Nov 06, 2025, 16:00 ET Curis Provides Third Quarter 2025 Business Update
in the US and EU. We are presenting three posters at the SNO annual meeting later this month, two in PCNSL and one in SCNSL. We are presenting at the ASH annual meeting in December with initial data from the ongoing frontline AML triplet study evaluating different dosing regimens of emavusertib, venetoclax,
More news about: Curis, Inc.
Nov 06, 2025, 08:00 ET Servier's New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research
/PRNewswire/ -- Servier today announced that it will present new and updated data at the 67th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2025, in Orlando, Florida. Presentations will highlight clinical and real-world data from Servier's hematology portfolio and underscore
More news about: Servier Pharmaceuticals
Nov 06, 2025, 07:24 ET DCW Limited Q2 FY26 EBITDA Surges 51% YoY; H1 PAT Rises 360%, Driven By Specialty Segment Growth and Alternate Energy-Substitution Gains
Segment Highlights Basic Chemicals: The Basic Chemicals segment (including Soda Ash, Caustic Soda, PVC and other intermediate chemicals) recorded Q2 FY2026 revenue of ₹394.55 crore, showing a 15.61% YoY growth (Q2 FY2025:
More news about: DCW Limited
Nov 06, 2025, 07:22 ET Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
of preclinical data for its first-in-class, wild-type–sparing JAK2-JH2/V617F inhibitor ZE74-0282 at the 67th American Society of Hematology (ASH) Annual Meeting. The company also confirmed plans to initiate first-in-human clinical studies in December 2025.
More news about: Eilean Therapeutics
Nov 06, 2025, 06:45 ET Core Natural Resources Reports Third Quarter 2025 Results
demonstrated elevated ash-basis concentrations of certain rare earth elements ("REEs") and critical minerals ("CMs"), particularly at the top and bottom of the coal seam. The drill core and grab samples from coal seam margins at the Black Thunder mine contained average dry ash-basis concentrations in
More news about: Core Natural Resources
Nov 06, 2025, 05:28 ET SELFRIDGES & DISNEY INVITE YOU TO 'A MOST MAGICAL CHRISTMAS'
Selfridges will screen a curated programme of classic Disney movies, followed by two upcoming releases, Zootropolis 2 and Avatar: Fire and Ash. Disney Theatrical Group will deliver one-of-a-kind workshops and live performances at Manchester Trafford and special surprise pop-up performances
More news about: Disney Consumer Products
Nov 05, 2025, 12:37 ET Ash Brokerage announces Chris Foley as VP of Long-Term Care
continue Ash Brokerage's growth of linked benefit and traditional LTC planning FORT WAYNE, Ind., Nov. 5, 2025 /PRNewswire/ -- Ash Brokerage LLC ("Ash"), a leading
More news about: Ash Brokerage, LLC
Nov 05, 2025, 08:00 ET Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings
today announced its participation at the upcoming Society of Immunotherapy in Cancer (SITC) 2025 Annual Meeting and American Society of Hematology (ASH) 2025 Annual Meeting. The company will present new preclinical and translational data supporting the advancement of its clinical pipelines, SynKIR™-110
More news about: Verismo Therapeutics
Nov 04, 2025, 16:41 ET Urban Ashes Redefines How K-12 Campuses Grow, Learn, and Thrive
sustainable materials and urban wood utilization, Hickman co-founded the original Urban Wood Project in southeast Michigan in response to the emerald ash borer. Over the past six years, Hickman has evolved Urban Ashes from a urban wood product manufacturer into a systems design and
More news about: Urban Ashes
Nov 04, 2025, 16:01 ET Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
Oral presentation featuring updated data from the dose escalation phase of the R289 Phase 1b study to be presented at the ASH Annual Meeting in December Updated 2025 Outlook: Total revenue of approximately
More news about: Rigel Pharmaceuticals, Inc.
Nov 04, 2025, 09:03 ET American Specialty Health Earns High Marks for Commitment to Quality and Security
required ASH to meet higher industry standards. In 2025, NCQA and URAC made major updates to their accreditation standards and ASH positively responded by updating its policies, reports, and systems to be compliant with these requirements. The HITRUST r2 re-certification led ASH to transition
More news about: American Specialty Health Incorporated
Nov 04, 2025, 08:15 ET Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6–9, 2025, in Orlando, Florida, USA.
More news about: Grit Biotherapeutics Co., Ltd.
Nov 04, 2025, 06:25 ET CMS Energy Prices Upsized Offering of $850 Million of 3.125% Convertible Senior Notes Due 2031
Engineers, and potential environmental remediation costs associated with these interpretations or decisions, including those that may affect Consumers' coal ash management or routine maintenance, repair, and replacement classification under New Source Review, a construction-permitting program under the Federal
More news about: CMS Energy
Nov 03, 2025, 22:23 ET 【2025 ASH】 亞盛醫藥Bcl-2抑制劑利沙托克拉兩項臨床研究入選，含1項口頭報告！
了公司的全球創新和開發實力。我們期待在後續會議期間與大家分享相關研究的詳實數據。未來，亞盛醫藥將進一步加速推進臨床開發，早日為患者帶來更多治療選擇。」 ASH 2025亞盛醫藥產品相關研究一覽：
More news about: 亞盛醫藥
Nov 03, 2025, 20:58 ET 口頭報告！維立志博5項血液腫瘤領域研究成果重磅登陸2025 ASH年會
View original content:https://www.prnewswire.com/apac/zh/news-releases/52025-ash-302603349.html SOURCE 維立志博
More news about: 維立志博
Nov 03, 2025, 20:22 ET 【2025 ASH】亞盛醫藥耐立克®多項研究入選，POLARIS-1研究數據首次發布
球注冊III期研究正在開展。此外，今年公司3個重點品種有多項進展入選ASH年會展示及報告，充分顯現了公司的全球創新和開發實力。我們期待在後續會議期間與大家分享相關研究的詳實數據。未來，亞盛醫藥將進一步加速推進臨床開發，早日為患者帶來更多治療選擇。」 ASH 2025亞盛醫藥產品相關研究一覽：
More news about: 亞盛醫藥
Nov 03, 2025, 14:23 ET Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
spinal IL17–TNF-α/IL-6–p38 MAPK activation in sickle cell disease. (Abstract #abs25-7273). #abs25-7273 received the 2025 ASH Abstract Achievement Award. About Sickle Cell Disease
More news about: Vascarta Inc
Nov 03, 2025, 13:31 ET Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting
hematologic conditions to diagnose accurately. Altogether, the datasets presented at ASH 2025 reflect Recordati's ongoing commitment to advancing care for people living with rare hematologic disorders." "The ASH Annual Meeting is an important opportunity to showcase research advances in
More news about: Recordati
Nov 03, 2025, 10:45 ET Recovered Carbon Black Market is expected to generate a revenue of USD 10.80 Billion by 2032, Globally, at 5.2% CAGR: Verified Market Research®
Type Primary Carbon Black Inorganic Ash Recovered Carbon Black Market, by Application
More news about: Verified Market Research
Nov 03, 2025, 09:05 ET Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
chronic myeloid leukemia (CML) patients, specifically in patients with atypical fusion transcripts, at the 67th Annual American Society of Hematology (ASH) 2025 Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida. "Approximately 2–4% of people living
More news about: Enliven Therapeutics, Inc.
Nov 03, 2025, 09:05 ET Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
prior therapies will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition on Sunday, December 7, 2025. In addition, the ASH Annual Meeting will feature four poster presentations with data for REZLIDHIA® (olutasidenib) for
More news about: Rigel Pharmaceuticals, Inc.
Nov 03, 2025, 09:01 ET Orna Therapeutics Announces Multiple Presentations Supporting its in vivo CAR Programs for Autoimmune Diseases at the 67th American Society of Hematology Annual Meeting
cells in vivo to treat autoimmune and oncology diseases, today announced upcoming presentations at the 67th American Society of Hematology (ASH) Annual Meeting being held December 6-9, 2025, in Orlando, Florida. The oral and poster presentations will highlight data supporting Orna's leading in
More news about: Orna Therapeutics
Nov 03, 2025, 09:01 ET TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
controlling the immunosuppressive capabilities of MDSCs was accepted for an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, FL from December 6-9, 2025. TuHURA will present these updated results along with a poster presentation
More news about: TuHURA Biosciences, Inc.
Nov 03, 2025, 09:00 ET Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
Sumitomo Pharma America, Inc. (SMPA) today announced three oral presentations and one poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition taking place in Orlando, Florida, from December 6-9, 2025. The presentations will include new clinical data supporting
More news about: Sumitomo Pharma America
Nov 03, 2025, 07:00 ET Sitero Acquires StudyOS and Launches SiteroAI, Becoming the Industry's First Truly AI-Powered CRO
Organization (CRO), today announced it has acquired the AI assets and business of studyOS - a novel eClinical AI technology provider and creator of Ash - the AI Clinical Trial Agent.
More news about: Sitero, LLC